FeesSafety
Pluang+

Iambic Therapeutics presents promising preclinical data for two AI-designed cancer drug candidates IAM-C1 and IAM217.

Market News
18 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Iambic Therapeutics presents promising preclinical data for two AI-designed cancer drug candidates IAM-C1 and IAM217.

Iambic Therapeutics announced positive preclinical results for IAM-C1, a dual CDK2/4 inhibitor effective against resistant breast cancer models, and IAM217, a brain-penetrant KIF18A inhibitor showing strong tumor regression in multiple cancer models including brain metastases. Both drugs were developed using Iambic's AI-driven molecular superintelligence platform and are advancing toward clinical trials, with IAM217 already cleared for Phase 1/2 and IAM-C1's IND submission expected by Q4 2026. These developments highlight Iambic's innovative approach to cancer treatment and its potential to address drug resistance and chromosomal instability in tumors.

Iambic's preclinical cancer drug data provides context for the health sector's trading activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 18, 2026 19:21 WIB: out of 150 priced health-sector US stocks, 55 rose and 86 fell. Medline Inc. (MDLN) traded at USD 36.45 with a 3.26% decline and a typical hold time of 8 days, contrasting with Ginkgo Bioworks (DNA) at USD 8.59 which rose 3.25% but saw 100% sell orders and a 10-day hold time. Abeona Therapeutics (ABEO) increased 3.08% to USD 2.68, with 97% sell orders and a longer typical hold time of 22 days.

More News

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
13 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App